Since its creation in 2008, IRICoR combines business and leading-edge research.
Our successful roadmap, with almost 15 years of significant achievements, testifies to our commitment to propel the development of novel therapies with a true impact on the health and life of Canadians.
The significant support of the Canadian government, as part of the 2018 edition of the Centre of Excellence in Commercialization and Research (CECR) Program, as well as that of the Quebec government, allows us to expand our research maturation activities toward commercialization across Canada, while contributing to the promotion of innovation and entrepreneurship among the next generation of life science leaders.
In just 15 years, IRICoR has achieved or significantly contributed to the following achievements:
4 companies created (3 active) (ExcellThera; Epitopea; Domain Therapeutics NA )
∾ 60 patent families generated
27 strategic partnerships with industry
Close to 70 million dollars in foreign investment specifically intended for research and development carried out in Canada
Over 60 projects with public and private partners
More than 100 project financings
30 licensing contracts with industry leaders
Contribution to the initiation of 8 clinical trials
5 pan-Canadian calls for projects launched